(19) World Intellectual Property Organization

International Bureau

(43) International Publication Date 7 June 2007 (07.06.2007)





PCT

(10) International Publication Number WO 2007/063286 A3

(51) International Patent Classification: *A61K 31/155* (2006.01) *A61K 51/04* (2006.01)

(21) International Application Number:

PCT/GB2006/004423

(22) International Filing Date:

28 November 2006 (28.11.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/740,464

29 November 2005 (29.11.2005) US

(71) Applicant (for all designated States except US): HAM-MERSMITH IMANET LIMITED [GB/GB]; Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): ARSTAD, Erik [NO/GB]; HAMMERSMITH IMANET LIMITED, Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN (GB). HENRIKSEN, Gjermund [NO/NO]; Department of Chemistry, University of Oslo, PO Box 1033 -Blindern, N-0315 Olso (NO).
- (74) Agent: HAMMETT, Audrey, Grace, Campbell; GE Healthcare Limited, Amersham Place, Little Chalfont, Buckinghamshire HP9 7NA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:

 3 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AMIDINE DERIVATIVES FOR IN VIVO IMAGING



(57) Abstract: The invention relates to a compound of formula (I) having use for *in vivo* imaging of the NR2B subtype of the NMDA receptor.





INTERNATIONAL SEARCH REPORT

International application No PCT/GB2006/004423

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/155 A61K51/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic da	ata base consulted during the international search (name of data b	ase and, where pract	cal, search terms used)
EPO-Int	ernal, CHEM ABS Data, WPI Data, BI	OSIS. EMBAS	<u> </u>	
		,		
			<u> </u>	
C. DOCUME	NTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where appropriate, of the r	elevant passages		Relevant to claim No.
χ .	TERENCE G. HAMILL, JOHN A. MCCAU DONALD BURNS: "The synthesis of	JLEY, H.		1,3,6-11
	<pre>benzamidine-containing NR2B-sele receptor ligand labelled with tr fluorine-18"</pre>			
	JOURNAL OF LABELLED COMPOUNDS AN RADIOPHARMACEUTICALS, vol. 48, no. 1,	ID		
	30 November 2004 (2004-11-30), p XP002453464	ages 1-10,		
, '	cited in the application page 1, paragraph 1 page 2, paragraph 2			
	page 3, paragraph 2 page 8, paragraph 2 figure 2; compound 2C			
		-/		
X Furth	er documents are listed in the continuation of Box C.	X See patent	family annex.	
	,	M Goo patent	ramiy amox.	
"A" documei conside	nt defining the general state of the art which is not are to be of particular relevance	"T" later document p or priority date cited to unders invention	oublished after the inte and not in conflict with land the principle or the	rnational filing date the application but eory underlying the
"E" earlier document but published on or after the international filling date "L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another		cannot be cons involve an inve	•	be considered to cument is taken alone
citation O' docume other m	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or leans	cannot be cons document is co ments, such co	ticular relevance; the c sidered to involve an inv mbined with one or mo mbination being obviou	ventive step when the ore other such docu-
"P" documer later tha	nt published prior to the international filing date but an the priority date claimed	in the art.	per of the same patent	
Date of the a	ctual completion of the international search	Date of mailing	of the international sea	rch report
17	October 2007	12/11/	/2007	
Name and m	alling address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized office	er	
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	01 aus	son, Jenny	

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/004423

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
Α	WO 00/67751 A (MERCK & CO INC [US]; CLAIBORNE CHRISTOPHER F [US]; LIVERTON NIGEL J [U) 16 November 2000 (2000-11-16) cited in the application page 1, line 5 - line 14 page 19 - page 32; compounds 15, 16, 20, 21, 23-28, 46-57, 59-61, 63, 79, 80	
A	CLAIBORNE, CHRISTOPHER F. ET AL: "Orally Efficacious NR2B-Selective NMDA Receptor Antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 13(4), 697-700 CODEN: BMCLE8; ISSN: 0960-894X, 2003, XP002453465 page 698, column 1, paragraph 1 table 1; compounds 13-18, 24-30 table 2; compounds 32-35 page 699, column 2, paragraph 2	
Α	WO 01/30330 A (MERCK SHARP & DOHME [GB]; KULAGOWSKI JANUSZ JOZEF [GB]) 3 May 2001 (2001-05-03) cited in the application page 11, line 28 - line 34 page 16, line 16 - page 18, line 5	
Α	WATERHOUSE R N: "Imaging the PCP site of the NMDA ion channel" NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 30, no. 8, November 2003 (2003-11), pages 869-878, XP004482851 ISSN: 0969-8051 page 870, column 1	
P,X	ARSTAD ET AL: "Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[<11>C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 14, no. 18, 15 September 2006 (2006-09-15), pages 6307-6313, XP005605292	1,3,6-11
	ISSN: 0968-0896 page 6307, column 2, paragraph 2 figures scheme,1 page 6308, column 2, paragraph 3 - page 6309, column 1, paragraph 1 page 6310, column 1, paragraph 2	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2006/004423

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0067751	A	16-11-2000	AU CA EP JP	4828300 A 2372496 A1 1178792 A1 2002544162 T	21-11-2000 16-11-2000 13-02-2002 24-12-2002
WO 0130330	A	03-05-2001	AU CA EP JP	1153601 A 2386441 A1 1235572 A2 2003512422 T	08-05-2001 03-05-2001 04-09-2002 02-04-2003